Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanotechnology Gold Rush Yields Crowded, Entangled Patents

Abstract:
New report from Lux Research and Foley & Lardner LLP assesses 1,084 nanotech patents; finds that nanotech winners and losers could be decided by courts and not consumers

Nanotechnology Gold Rush Yields Crowded, Entangled Patents

New York, NY | April 21, 2005

A gold-rush mentality has taken hold in nanotechnology, and patents are the precious resource being hoarded. As of late March 2005, 3,818 U.S. nanotechnology patents had been issued with another 1,777 patent applications awaiting judgment. But entrepreneurs’ ability to turn their patents into cash may be limited by crowded claims that overlap with one another, according to a new report from Lux Research entitled “The Nanotech Intellectual Property Landscape.” The report was developed in partnership with patent attorneys in the nanotechnology practice at law firm Foley & Lardner LLP.

“Nanotech researchers worldwide are steadily filing patents in the hopes of creating ‘tollbooths’ for future products incorporating nanomaterials,” said Lux Research Vice President of Research Matthew Nordan. “Nanomaterials – the ‘building blocks’ of nanotechnology, like carbon nanotubes and quantum dots – have seen particular focus. Our comprehensive patent review shows that the patent landscape for these materials is complex and fragmented. Because so many patents have been filed relating to nanomaterials, and so many of them seem to overlap, companies that want to use these building blocks in products will be forced to license patents from many different sources in order to do so.”

To analyze the landscape of nanotechnology IP, Lux Research and Foley & Lardner systematically reviewed 1,084 U.S. patents – representing 19,485 claims – that relate to five nanomaterials: 1) dendrimers, 2) quantum dots, 3) carbon nanotubes, 4) fullerenes, and 5) nanowires. The patents were reviewed manually on a claim-by-claim basis; no software automation was used. The team broke down patents for each nanomaterial platform by application and rated them according to how much “white space” remains for new claims and how entangled existing patents look, using a rigorous, quantitative methodology.

The report concludes that:

  • Dendrimers pose the biggest question mark, scoring low on white space and freedom from entanglement for all commercially significant applications. A large number of relevant claims have been assigned from pioneer Dow to one start-up company, Dendritic Nanotechnologies.
  • Quantum dots have particularly knotty entanglement for general claims that cover the materials themselves and not any specific application. This fact casts doubt on the commercial value of quantum dot IP.
  • Carbon nanotube patents look messy in electronics, but promising in energy and healthcare and cosmetics. The common assumption that carbon nanotube patents are both numerous and overlapping across all important application categories is incorrect.
  • Fullerenes look relatively unentangled, but crowded with abandoned patents. The good news: Fullerenes show less entanglement than the previous three categories. The bad news: Many patents issued may be useless – inventors have given up on a third of them by failing to pay patent maintenance fees.
  • Nanowire patents number few and seem distinct – but Nanosys looms large. Nanowire patents offer a good opportunity to license the most important ones on an exclusive basis without worrying about IP entanglement – so good that start-up Nanosys has already attempted to do it.

"Looking into the future, while some nanotech patent litigation is inevitable, those who have their own patents will have some leverage with which to avoid a self-destructive IP war," said Stephen B. Maebius, chair of the Nanotechnology Industry Team at Foley & Lardner LLP. "The stage is set for a wave of cross-licensing agreements by start-ups, and bundles of IP for specific applications licensed by groups of large corporations. We advise companies filing nanotech patents to go for claims of intermediate scope - not just broad claims - recognizing that the courts might not uphold all broad claims, as has been the case with a number of biotech patents. Firms licensing nanotech IP should define fields of use with great care, given that most nanotech inventions cut across multiple industries and may find commercial applications in diverse fields."

The report and its underlying data set are available immediately to clients of Lux Research’s Nanotechnology Strategies advisory service. For information on how to become a client, contact Steve Mills at (646) 723-0163.

####

About Lux Research
Lux Research is the world's leading nanotechnology research and advisory firm. We help our clients make better decisions to profit from nanoscale science and technology, tapping into our analysts' unique expertise and unrivaled network. Our clients include top decision makers at large corporations, portfolio managers and analysts at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers. To get connected and for more information, visit www.luxresearchinc.com

About Foley & Lardner LLP
Foley & Lardner LLP is a provider of legal counsel to global companies. The firm's experience encompasses a full range of corporate legal services. Foley & Lardner's attorneys understand today's most complex business issues including corporate governance, securities enforcement, litigation, mergers and acquisitions, intellectual property and IP litigation, labor and employment, and tax. The firm offers total solutions in the nanotechnology, life sciences, automotive, e-business and information technology, energy, financial services, food, health care, insurance, golf and resort services, and sports industries. Our Web site can be found at www.foley.com.


Copyright © Lux Research

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanotubes/Buckyballs

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Effects of Carbon Nanotubes Studied on Pregnant Mothers April 12th, 2014

Nanotech Business Review 2013-2014 April 9th, 2014

Scientists Succeed in Simultaneous Determination of Acetaminophen, Codeine in Drug Samples April 9th, 2014

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Materials/Metamaterials

Nanomaterial Outsmarts Ions April 22nd, 2014

Thinnest feasible membrane produced April 17th, 2014

INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014

Engineers develop new materials for hydrogen storage April 15th, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanoparticles cause cancer cells to self-destruct April 3rd, 2014

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE